These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. Argenti D; Jensen BK; Hensel R; Bordeaux K; Schleimer R; Bickel C; Heald D J Clin Pharmacol; 2000 Jul; 40(7):770-80. PubMed ID: 10883419 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Derendorf H; Möllmann H; Grüner A; Haack D; Gyselby G Clin Pharmacol Ther; 1986 Mar; 39(3):313-7. PubMed ID: 3948470 [TBL] [Abstract][Full Text] [Related]
5. Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. Wilson AM; Clark DJ; McFarlane L; Lipworth BJ Eur J Clin Pharmacol; 1997; 53(1):33-7. PubMed ID: 9349927 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. Derendorf H; Hochhaus G; Rohatagi S; Möllmann H; Barth J; Sourgens H; Erdmann M J Clin Pharmacol; 1995 Mar; 35(3):302-5. PubMed ID: 7608322 [TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. Argenti D; Shah B; Heald D J Clin Pharmacol; 1999 Jul; 39(7):695-702. PubMed ID: 10392324 [TBL] [Abstract][Full Text] [Related]
8. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412 [TBL] [Abstract][Full Text] [Related]
9. Comparison of glucocorticoid-binding proteins in normal and neoplastic mammary tissues of the rat. Goral JE; Wittliff JL Biochemistry; 1975 Jul; 14(13):2944-52. PubMed ID: 238578 [TBL] [Abstract][Full Text] [Related]
10. Additional studies on triamcinolone acetonide use and misuse in sports: Elimination profile after intranasal and high-dose intramuscular administrations. Coll S; Monfort N; Alechaga É; Matabosch X; Pérez-Mañá C; Ventura R Steroids; 2019 Nov; 151():108464. PubMed ID: 31344406 [TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid binding in the hen oviduct. Moudgil VK; Healy SP; Shaffer TL; Szocik JF Biochem J; 1981 Jul; 198(1):91-9. PubMed ID: 7326005 [TBL] [Abstract][Full Text] [Related]
12. The clearance of intravitreal triamcinolone acetonide. Schindler RH; Chandler D; Thresher R; Machemer R Am J Ophthalmol; 1982 Apr; 93(4):415-7. PubMed ID: 7072807 [TBL] [Abstract][Full Text] [Related]
13. Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Zacharias LC; Lin T; Migon R; Ghosn C; Orilla W; Feldmann B; Ruiz G; Li Y; Burke J; Kuppermann BD Retina; 2013 Mar; 33(3):522-31. PubMed ID: 22990317 [TBL] [Abstract][Full Text] [Related]
14. An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. Bodick N; Lufkin J; Willwerth C; Kumar A; Bolognese J; Schoonmaker C; Ballal R; Hunter D; Clayman M J Bone Joint Surg Am; 2015 Jun; 97(11):877-88. PubMed ID: 26041848 [TBL] [Abstract][Full Text] [Related]
15. Comparison of in vivo activation of triamcinolone acetonide- and RU 38486-receptor complexes in the CEM-C7 and IM-9 human leukemic cell lines. Schmidt TJ Cancer Res; 1989 Aug; 49(16):4390-5. PubMed ID: 2743328 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of intravenous liposomal triamcinolone acetonide in the rabbit. Abraham I; Hilchie JC; Mezei M J Pharm Sci; 1983 Dec; 72(12):1412-5. PubMed ID: 6663477 [TBL] [Abstract][Full Text] [Related]
17. [Effect of the external use of triamcinolone acetonide under foil occlussive dressings on the plasma cortisol level and on the diurnal rhythm of plasma cortisol]. Hartmann F; Lahmann JJ Hautarzt; 1977 Apr; 28(4):198-202. PubMed ID: 559653 [TBL] [Abstract][Full Text] [Related]
18. Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes. Oliveira RC; Messias A; Siqueira RC; Bonini-Filho MA; Haddad A; Damico FM; Maia-Filho A; Crispim PT; Saliba JB; Ribeiro JA; Scott IU; Cunha AS; Jorge R Curr Eye Res; 2012 Jan; 37(1):55-61. PubMed ID: 22029458 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of triamcinolone acetonide palmitate and triamcinolone acetonide in beagle dog plasma by UPLC-MS/MS and its application to a long-term pharmacokinetic study of triamcinolone acetonide palmitate lipid emulsion injection. Liu H; Yang M; Wu P; Guan J; Men L; Lin H; Tang X; Zhao Y; Yu Z J Pharm Biomed Anal; 2015 Feb; 104():105-11. PubMed ID: 25497892 [TBL] [Abstract][Full Text] [Related]
20. Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro. Obata R; Iriyama A; Inoue Y; Takahashi H; Tamaki Y; Yanagi Y Br J Ophthalmol; 2007 Jan; 91(1):100-4. PubMed ID: 16987905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]